Therapeutic Allogeneic Lymphocytes and Aldesleukin in Treating Patients With High-Risk or Recurrent Myeloid Leukemia After Undergoing Donor Stem Cell Transplant

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00052598
Recruitment Status : Terminated
First Posted : January 27, 2003
Last Update Posted : February 15, 2017
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Fred Hutchinson Cancer Research Center

No Study Results Posted on for this Study
  Recruitment Status : Terminated
  Actual Primary Completion Date : November 2009
  Actual Study Completion Date : June 2011
  Certification/Extension First Submitted : February 13, 2017